Founded in 1998, Illumina started as a manufacturer of microarrays – a chip consisting of a small glass plate, similar to those used to make computer microchips. DNA microarrays are used to determine whether the DNA from an individual contains a mutation in genes.
Moving into the sequencing space was the next step for Illumina and a transformative one for the organization. In 2006, with the acquisition of Solexa, a then small sequencing technology company, Illumina rapidly established itself as a market leader, with the steadfast commitment to drive down the cost of genomic sequencing.
By 2014, Illumina took significant steps towards becoming a global leader in clinical diagnostics, including screening of genetic abnormalities and the broadest non-invasive prenatal test available today. We’ve transformed from Research Use Only (RUO) prior to 2014 to present, where half of our business is clinically focused.